Liver Transplantation as Treatment in a Massive Metastasis From Gruber-Frantz Pancreatic Tumor: A Case Report

Dovigo, Alba Gómez; Díaz, M. Berdeal; Gutiérrez, Manuel Gómez; Sellés, C. Fernández; Grobas, J. Pérez; Valladares, Manuel; Suárez, Francisco; Marini, Milagros

doi:10.1016/j.transproceed.2011.05.029

Cited by 21 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[6][7][8]11 In accordance with other findings, 50% of the current patients were asymptomatic at presentation, while others presented with diarrhoea and abdominal pain, distension or masses. 12,13 Since abdominal discomfort and pain are qualitative parameters, useful SPN markers are required.…”

Section: Discussionsupporting

confidence: 89%

“…[1][2][3][4] Despite improvements in SPN detection, diagnosis and reporting, 4-6 misdiagnosis as pancreatic adenocarcinoma and lack of consensus regarding treatment remain major obstacles in disease management. 5,7 Studies have shown that SPN usually occurs in young women, 6,8 but clinical manifestations, pathological features and treatment modalities vary. The aim of the current study, therefore, was to analyse the clinicopathological characteristics and treatment outcomes of patients with SPN, retrospectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective analysis of 102 cases of solid pseudopapillary neoplasm of the pancreas in China

Wang

et al. 2013

J Int Med Res

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Retrospective analysis of 102 cases of solid pseudopapillary neoplasm of the pancreas in China

Wang

et al. 2013

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…Sporadic reports found that neoadjvant chemotherapy or radiation therapy could benefit some patients with unresectable tumors[ 49 - 51 ]. Other therapeutic methods including radiofrequency ablation[ 52 ], transcatheter arterial chemoembolization[ 53 ], selective internal radiotherapy (SIRT)[ 54 ] and liver transplantation[ 55 ] have also been reported to achieve good results for patients with liver metastasis from SPTP. However, despite a better understanding of this disease, individual treatment of unresectable or metastatic SPTP requires further study.…”

Section: Treatment Of Malignant Sptpmentioning

confidence: 99%

Prediction of malignancy and adverse outcome of solid pseudopapillary tumor of the pancreas

Yang

2018

WJGO

View full text Add to dashboard Cite

Since solid pseudopapillary tumor of the pancreas (SPTP) was officially classified by the World Health Organization in 1996, SPTP has recently received special attention in the literature. Studies have shown that SPTP is a heterogeneous tumor, with a small percentage of patients harboring aggressive behaviors. However, criteria for malignancy grade in SPTP have not been well established. The prognosis of SPTP is generally good, with cases having a chance for long-term survival even with recurrence and/or metastasis after surgical resection. The current American Joint Committee on Cancer/Union for International Cancer Control tumor, node, metastasis staging system is not specific to SPTP. The lack of a predictive staging classification that accurately describes the heterogeneity of this disease hinders meaningful research into optimal individualized therapy. Here we summarize and discuss the associated factors proposed for appraisal of the malignant potential and adverse outcome of SPTP.

show abstract

“…Longer recurrence-free survival was later reported by Łągiewska et al[ 63 ], whose patient was free of disease after 5 years from cadaveric OLT. However, in two other patients, disease recurred within 1 and 4 years[ 64 , 65 ].…”

Section: Pseudopapillarymentioning

confidence: 99%

One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches

Niger

Prisciandaro

Antista

et al. 2020

WJGO

View full text Add to dashboard Cite

Exocrine pancreatic neoplasms represent up to 95% of pancreatic cancers (PCs) and are widely recognized among the most lethal solid cancers, with a very poor 5-year survival rate of 5%-10%. The remaining < 5% of PCs are neuroendocrine tumors that are usually characterized by a better prognosis, with a median overall survival of 3.6 years. The most common type of PC is pancreatic ductal adenocarcinoma (PDAC), which accounts for roughly 85% of all exocrine PCs. However up to 10% of exocrine PCs have rare histotypes, which are still poorly understood. These subtypes can be distinguished from PDAC in terms of pathology, imaging, clinical presentation and prognosis. Additionally, due to their rarity, any knowledge regarding these specific histotypes is mostly based on case reports and a small series of retrospective analyses. Therefore, treatment strategies are generally deduced from those used for PDAC, even if these patients are often excluded or not clearly represented in clinical trials for PDAC. For these reasons, it is essential to collect as much information as possible on the management of PC, as assimilating it with PDAC may lead to the potential mistreatment of these patients. Here, we report the most significant literature regarding the epidemiology, typical presentation, possible treatment strategies, and prognosis of the most relevant histotypes among rare PCs.

show abstract

Liver Transplantation as Treatment in a Massive Metastasis From Gruber-Frantz Pancreatic Tumor: A Case Report

Cited by 21 publications

References 4 publications

Retrospective analysis of 102 cases of solid pseudopapillary neoplasm of the pancreas in China

Retrospective analysis of 102 cases of solid pseudopapillary neoplasm of the pancreas in China

Prediction of malignancy and adverse outcome of solid pseudopapillary tumor of the pancreas

One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches

Contact Info

Product

Resources

About